top of page
Backgrounds.jpg

The voice of Colville and northeastern Washington since 1896

|

September 15, 2026

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dianthus Therapeutics, Inc. - Common Stock (NQ:DNTH)

75.37 -2.21 (-2.85%)
Delayed Quote Updated: 12:12 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Dianthus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharma
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics to Participate in Three Investor Conferences During September
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics to Participate in Two Investor Conferences
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics to Participate in Four Investor Conferences During November
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page